Singapore, Nov. 9 -- Australia's Monash University researchers have used the world's largest multiple sclerosis (MS) registry, MSBase, to provide evidence that will help those with MS take the best medicine for them.

People with MS often need to switch drugs to fully control their disease. These switch decisions are complex because until now there has been no good evidence to choose one new drug over another.

This new study has determined disease outcomes for three common drugs that people switch to after stopping the popular MS drug fingolimod due to disease breakthrough or side effects. The results will enable people with MS and their care teams to make evidence-based decisions about medication. Fingolimod is approved as a first-line ...